The FDA just fired a double-barreled response to breast cancer. On back-to-back days, the agency approved Pfizer's palbociclib (Ibrance) as a first-line maintenance treatment for HR-positive/HER2-positive metastatic breast cancer — the first CDK4/6 inhibitor with that indication regardless of HER2 status — and cleared Gilead's Trodelvy for two new first-line uses in triple-negative breast cancer. The PATINA trial showed patients on palbociclib went **44.3...